Targeting integrated stress response with ISRIB combined with imatinib treatment attenuates RAS/RAF/MAPK and STAT5 signaling and eradicates chronic myeloid leukemia cells. The gene discussed is RAF1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.